The non-nucleoside inhibitor RG108 (N-phthaloyl-l-tryptophan 1) and selective non-nucleoside DNMT1 inhibitors in the DC_05 series of compounds (DC_501 and DC_517) can also play an anti-cancer role by inducing DNA hypomethylation to restore the expression of TSGs [91,92]. Here, DNMT1 is linked to cancer.